Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
Kristian M. Hargadon, Coleman E. Johnson, Corey J. Williams
International Immunopharmacology (2018) Vol. 62, pp. 29-39
Closed Access | Times Cited: 1053

Showing 1-25 of 1053 citing articles:

Cancer statistics, 2020
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal
CA A Cancer Journal for Clinicians (2020) Vol. 70, Iss. 1, pp. 7-30
Open Access | Times Cited: 18667
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo
Nature reviews. Immunology (2020) Vol. 20, Iss. 11, pp. 651-668
Open Access | Times Cited: 3206
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 822
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
Claudio Luchini, Frédéric Bibeau, M. Ligtenberg, et al.
Annals of Oncology (2019) Vol. 30, Iss. 8, pp. 1232-1243
Open Access | Times Cited: 813
Targeting Tumor-Associated Macrophages in Cancer
Paulina Pathria, Tiani L. Louis, Judith A. Varner
Trends in Immunology (2019) Vol. 40, Iss. 4, pp. 310-327
Closed Access | Times Cited: 797
mRNA vaccine for cancer immunotherapy
Lei Miao, Yu Zhang, Leaf Huang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 693
Monoclonal Antibodies in Cancer Therapy
David J. Zahavi, Louis M. Weiner
Antibodies (2020) Vol. 9, Iss. 3, pp. 34-34
Open Access | Times Cited: 613
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
David Y. Oh, Serena S. Kwek, Siddharth S. Raju, et al.
Cell (2020) Vol. 181, Iss. 7, pp. 1612-1625.e13
Open Access | Times Cited: 571
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 6, pp. e002435-e002435
Open Access | Times Cited: 553
The Next Decade of Immune Checkpoint Therapy
Padmanee Sharma, Bilal A. Siddiqui, Swetha Anandhan, et al.
Cancer Discovery (2021) Vol. 11, Iss. 4, pp. 838-857
Open Access | Times Cited: 544
Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer
Yuanyuan Zhang, Hongyan Chen, Hongnan Mo, et al.
Cancer Cell (2021) Vol. 39, Iss. 12, pp. 1578-1593.e8
Open Access | Times Cited: 489
The growing role of precision and personalized medicine for cancer treatment
Paulina Krzyszczyk, Alison Acevedo, Erika J. Davidoff, et al.
Deleted Journal (2018) Vol. 06, Iss. 03n04, pp. 79-100
Open Access | Times Cited: 484
The immunology of renal cell carcinoma
C. Marcela Díaz‐Montero, Brian I. Rini, James H. Finke
Nature Reviews Nephrology (2020) Vol. 16, Iss. 12, pp. 721-735
Closed Access | Times Cited: 343
Beyond immune checkpoint blockade: emerging immunological strategies
Shawn P. Kubli, Thorsten Berger, Daniel Vilarim Araújo, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 12, pp. 899-919
Closed Access | Times Cited: 339
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes, Gaëlle Vandermeulen, Véronique Préat
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 332
T cell receptor (TCR) signaling in health and disease
Kinjal Shah, Amr Al‐Haidari, Jianmin Sun, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 317
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Adel Naimi, Rebar N. Mohammed, Ahmed Raji, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 278
The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
Zhi Peng, Siyuan Cheng, Yan Kou, et al.
Cancer Immunology Research (2020) Vol. 8, Iss. 10, pp. 1251-1261
Open Access | Times Cited: 248
Next-generation stem cells — ushering in a new era of cell-based therapies
Erin A. Kimbrel, Robert Lanza
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 7, pp. 463-479
Closed Access | Times Cited: 232
The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy
Rik G.H. Lindeboom, Michiel Vermeulen, Ben Lehner, et al.
Nature Genetics (2019) Vol. 51, Iss. 11, pp. 1645-1651
Open Access | Times Cited: 231
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
Chunyong Ding, Zilan Song, Ancheng Shen, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 10, Iss. 12, pp. 2272-2298
Open Access | Times Cited: 230
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
Nicolas Jacquelot, Takahiro Yamazaki, María P. Roberti, et al.
Cell Research (2019) Vol. 29, Iss. 10, pp. 846-861
Open Access | Times Cited: 205
Immune checkpoints in the tumor microenvironment
Salman M. Toor, Varun Sasidharan Nair, Julie Decock, et al.
Seminars in Cancer Biology (2019) Vol. 65, pp. 1-12
Closed Access | Times Cited: 196
Low-Temperature Photothermal Therapy: Strategies and Applications
Xiulin Yi, Qiu‐Yi Duan, Fu‐Gen Wu
Research (2021) Vol. 2021
Open Access | Times Cited: 192
Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy
David M. Francis, Margaret P. Manspeaker, Alex Schudel, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 563
Open Access | Times Cited: 190
Page 1 - Next Page

Scroll to top